**Case 1**

**History and Physical**

Date: 01-09-2018

History of present illness: 65 year old male, urinary frequency 8-10. Nocturia 1-2. Feelings of urinary urgency. Urinary hesitancy. Smaller urine stream. No hematuria. No urinary loss of control. No dysuria. Unable to maintain erection. DRE was benign.

Patient self-referred 1-3-18 for OVS. Patient noted a 25 year h/o difficulty voiding, slow stream. He noted in his 40’s he had a testicle that swelled up and become painful, since then he has had dysuria and slowing of the stream. He was on doxazosin for about 3 years which seemed to help quite a bit, but then he had progression of the symptoms, changed to a generic medication that gave him palpitations and lightheadedness, he stopped the medication (doxazosin) and those symptoms were horrible. His most troublesome symptom was painful urination alleviated by the Flomax.

**Plan:** URO surgery scheduled.

**Operative Report**

Date: 1-18-2018

Preop/Preprocedure diagnosis: Urinary frequency; Nocturia; Smaller urine stream

Postop/Postprocedure diagnosis: Same

Procedure: Resection Prostate in Saline Transurethral

Preoperative diagnosis: Benign prostatic hypertrophy with obstruction

Postoperative diagnosis: Benign prostatic hypertrophy with obstruction

**Path Report**

Date: 1-18-2018

Diagnosis:

Prostate gland, TUR:

* Prostatic acinar adenocarcinoma, Gleason 3+4=7
* Tumor involves 5 chips and approximately 1% of the overall tissue

Gross description: Received fresh labeled “prostate” is a 14.6 gram, 6.5 x 6x2 cm aggregate of fragmented tan tissue. No distinct masses or lesions are grossly identified. Representative sections are submitted in 1-8, remaining tissue is entirely submitted in 9-18.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Case Scenario 1 | | | | | | | |
| Primary Site |  | MP Rule | |  | Clinical Grade | |  |
| Laterality |  |  | |  | Pathological Grade | |  |
| Histology |  | H Rule | |  | Post Therapy Grade | |  |
| Behavior |  |  | | | | | |
| Stage Data items | | | | | | | |
| Clinical Tumor Size |  | Pathological Tumor Size | |  | Tumor Size Summary | |  |
| AJCC Stage | | | | | | | |
| Clinical T |  | Pathological T | |  | Post-therapy T | |  |
| cT Suffix |  | pT Suffix | |  | pT Suffix | |  |
| Clinical N |  | Pathological N | |  | Post-therapy N | |  |
| cN Suffix |  | pN Suffix | |  | pN Suffix | |  |
| Clinical M |  | Pathological M | |  | Post-therapy M | |  |
| Clinical Stage |  | Pathological Stage | |  | Post-therapy Stage | |  |
| EOD & SSDI’s | |  | |  |  | |  |
| Summary Stage 2018 | |  | Diagnostic Staging Procedure | | |  | |
| EOD Primary Tumor | |  |  | | | | |
| Prostate Pathological Extension | |  | **Surgery Codes** | | | | |
| EOD Lymph Regional Nodes | |  | Surgical Procedure of Primary Site | | |  | |
| EOD Mets | |  | Scope of Regional Lymph Node Surgery | | |  | |
| Regional Nodes Positive | |  | Surgical Procedure/ Other Site | | |  | |
| Regional Nodes Examined | |  | **Systemic Therapy Codes** | | | | |
| Lymphovascular Invasion | |  | Chemotherapy | | |  | |
| PSA Lab value | |  | Hormone Therapy | | |  | |
| Number of Cores Positive | |  | Immunotherapy | | |  | |
| Number of Cores Examined | |  | Hematologic Transplant/Endocrine Procedure | | |  | |
| Gleason Score Clinical | |  | Systemic/Surgery Sequence | | |  | |
| Gleason Patterns Clinical | |  |  | | |  | |
| Gleason Score Pathological | |  |  | | |  | |
| Gleason Patterns Pathological | |  |  | | |  | |
| Gleason Tertiary Pattern | |  |  | | |  | |

**Case 2**

**5-9-2018: Radiation Oncology Consultation**

Pleasant 60-year old black gentleman found to have an elevated PSA of 10.6 on 3-20-18. PTA his DRE was normal feeling prostate without nodules or indurations. He underwent a transrectal ultrasound and biopsy on 4-20-18 and found to have adenocarcinoma of the prostate, Gleason score over 4+5.

**Medical history:** Adenocarcinoma of colon, arthritis, colon polyps, depression, diabetes, hepatitis C, hyperlipidemia, hypertension and prostate cancer on 4-20-18. Social Hx: former smoker, no alcohol. Fam Hx: negative for cancer.

**Assessment and Plan**: Recommend patient undergo external beam radiotherapy in conjunction with anti-hormonal therapy. Radiotherapy would consist of radiation at a dose 180 cGy per fraction for 43 fractions.

**Lab review**: 3-20-18: PSA 10.6

**Imaging review: 4-26-18:** CT of abdomen/pelvis no evidence of adenopathy or pelvic masses. 5-26-18: Bone scan does not show any evidence of osseous metastatic disease

**4-20-18 TRUS/Bx**: Left mid: Adenocarcinoma, Gleason 4+5=9 (1 core), Left base, lateral mid, lateral apex: adenocarcinoma, Gleason 3+4=7 (3 of 3 cores), Left apex and lateral base: adenocarcinoma, Gleason 4+3=7 (2 of 2 cores), Right mid, apex, lateral base, lateral mid, lateral apex: Adenocarcinoma Gleason 3+3=6 (5 of 5 cores), Right base negative (1 core). Perineural invasion present. LVI is not identified.

**8-23-18: Treatment Summary:** Impression/Plan: Adenocarcinoma of the prostate, Gleason 4+5, PSA 10.6 s/p biopsy

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment  Site | Energy | Dose/Fx (cGy) | # Fx | Dose correction (cGy) | Total Dose (cGy) | Start Date | End Date | Elapsed Days |
| 01Prost+  SV+LN | 10X | 180 | 25/25 | 0 | 4,500 | 6-18-2018 | 7-24-2018 | 36 |
| 02Prost+  SV | 10X | 180 | 5/5 | 0 | 900 | 7-25-2018 | 7-31-2018 | 6 |
| 03Pros  Boost | 10X | 180 | 13/13 | 0 | 2,340 | 8-1-2018 | 8-17-2018 | 16 |
| Total: |  |  |  |  | 7,740 | 6-18-2018 | 8-17-2016 | 60 |

**Hormone treatment:** 5-21-18 Lupron

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Case Scenario 2 | | | | | | | |
| Primary Site |  | MP Rule | |  | Clinical Grade | |  |
| Laterality |  |  | |  | Pathological Grade | |  |
| Histology |  | H Rule | |  | Post Therapy Grade | |  |
| Behavior |  |  | | | | | |
| Stage Data items | | | | | | | |
| Clinical Tumor Size |  | Pathological Tumor Size | |  | Tumor Size Summary | |  |
| AJCC Stage | | | | | | | |
| Clinical T |  | Pathological T | |  | Post-therapy T | |  |
| cT Suffix |  | pT Suffix | |  | pT Suffix | |  |
| Clinical N |  | Pathological N | |  | Post-therapy N | |  |
| cN Suffix |  | pN Suffix | |  | pN Suffix | |  |
| Clinical M |  | Pathological M | |  | Post-therapy M | |  |
| Clinical Stage |  | Pathological Stage | |  | Post-therapy Stage | |  |
| EOD & SSDI’s | |  | |  |  | |  |
| Summary Stage 2018 | |  | Diagnostic Staging Procedure | | |  | |
| EOD Primary Tumor | |  |  | | | | |
| Prostate Pathological Extension | |  | **Surgery Codes** | | | | |
| EOD Lymph Regional Nodes | |  | Surgical Procedure of Primary Site | | |  | |
| EOD Mets | |  | Scope of Regional Lymph Node Surgery | | |  | |
| Regional Nodes Positive | |  | Surgical Procedure/ Other Site | | |  | |
| Regional Nodes Examined | |  | **Systemic Therapy Codes** | | | | |
| Lymphovascular Invasion | |  | Chemotherapy | | |  | |
| PSA Lab value | |  | Hormone Therapy | | |  | |
| Number of Cores Positive | |  | Immunotherapy | | |  | |
| Number of Cores Examined | |  | Hematologic Transplant/Endocrine Procedure | | |  | |
| Gleason Score Clinical | |  | Systemic/Surgery Sequence | | |  | |
| Gleason Patterns Clinical | |  | Date systemic therapy | | |  | |
| Gleason Score Pathological | |  |  | | |  | |
| Gleason Patterns Pathological | |  |  | | |  | |
| Gleason Tertiary Pattern | |  |  | | |  | |

|  |  |
| --- | --- |
| Phase I Radiation | |
| Phase I Primary Treatment Volume | 64 |
| Phase I to Draining Lymph Nodes | 06 |
| Phase I Treatment Modality | 02 |
| Phase I External Beam Planning Technique | 05 |
| Phase I Dose Per Fraction (cGy) | 00180 |
| Phase I Number of Fractions | 025 |
| Phase I Total Dose (cGy) | 004500 |
| Phase II Radiation | |
| Phase II Primary Treatment Volume | 64 |
| Phase II to Draining Lymph Nodes | 00 |
| Phase II Treatment Modality | 02 |
| Phase II External Beam Planning Technique | 05 |
| Phase II Dose Per Fraction (cGy) | 00180 |
| Phase II Number of Fractions | 005 |
| Phase II Total Dose (cGy) | 000900 |
| Phase III Radiation | |
| Phase III Primary Treatment Volume | 64 |
| Phase III to Draining Lymph Nodes | 00 |
| Phase III Treatment Modality | 02 |
| Phase III External Beam Planning Technique | 05 |
| Phase III Dose Per Fraction (cGy) | 00180 |
| Phase III Number of Fractions | 013 |
| Phase III Total Dose (cGy) | 002340 |
|  | |
| Date RT Started | 06-18-2018 |
| Date RT Ended | 08-17-2018 |
| # of Phases of RT to this Volume | 03 |
| RT Discontinued Early | 01 |
| Total Dose | 007740 |

**Case 3**

**Clinical History/Diagnosis**: 47 year old male with elevated PSA, BPH, and family history of prostate cancer

**10-22-2018: Prostate TRUS/BX**: Adenoca Gleason 4+3 in 2 cores on left. All other cores negative

**12-14-2018: Robotic assisted laparoscopic radical prostatectomy**

Specimen submitted:

1. Prostate
2. Bladder neck margin
3. Regional lymph nodes

**Diagnosis:**

1. Prostate, prostatectomy
   1. Prostatic adenocarcinoma, Gleason 3+4=7 (grade group 2), occupying approximately 30% of sampled prostate gland
   2. Positive for bladder neck invasion, bilateral
   3. Positive surgical margins in left apex (4 mm linear extent) and left bladder neck/base (11 mm linear extent)
   4. Benign seminal vesicles
   5. See CAP summary below
2. Bladder neck margin, excision
   1. No malignancy identified
3. Regional lymph nodes
   1. 1 of 4 notes positive for met adenoca

**College of American Pathologists**

Surgical Pathology Cancer Case Summary (Checklist)

Procedure: Radical Prostatectomy

Histologic Type: Acinar adenocarcinoma

Histologic grade: Gleason pattern score and grade group:

Primary Gleason Pattern: Pattern 3

Secondary Gleason Pattern: Pattern 4

Total Gleason Score: 7

Grade Group: Grade group 2

Tumor Quantitation: Estimated percentage of prostate involved by tumor: 30%

Extraprostatic extension: Present, non-focal (bilateral bladder neck/prostatic base involvement)

Urinary Bladder neck invasion: Present

Margins: Non-limited (? 3 mm)

Location of positive margins: Left apical, left bladder neck

Treatment effect: No known pre-surgical therapy

Lymphovascular invasion: Not identified

Regional Lymph nodes: 1 of 4 LN’s positive

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Case Scenario 3 | | | | | | | |
| Primary Site |  | MP Rule | |  | Clinical Grade | |  |
| Laterality |  |  | |  | Pathological Grade | |  |
| Histology |  | H Rule | |  | Post Therapy Grade | |  |
| Behavior |  |  | | | | | |
| Stage Data items | | | | | | | |
| Clinical Tumor Size |  | Pathological Tumor Size | |  | Tumor Size Summary | |  |
| AJCC Stage | | | | | | | |
| Clinical T |  | Pathological T | |  | Post-therapy T | |  |
| cT Suffix |  | pT Suffix | |  | pT Suffix | |  |
| Clinical N |  | Pathological N | |  | Post-therapy N | |  |
| cN Suffix |  | pN Suffix | |  | pN Suffix | |  |
| Clinical M |  | Pathological M | |  | Post-therapy M | |  |
| Clinical Stage |  | Pathological Stage | |  | Post-therapy Stage | |  |
| EOD & SSDI’s | |  | |  |  | |  |
| Summary Stage 2018 | |  | Diagnostic Staging Procedure | | |  | |
| EOD Primary Tumor | |  |  | | | | |
| Prostate Pathological Extension | |  | **Surgery Codes** | | | | |
| EOD Lymph Regional Nodes | |  | Surgical Procedure of Primary Site | | |  | |
| EOD Mets | |  | Scope of Regional Lymph Node Surgery | | |  | |
| Regional Nodes Positive | |  | Surgical Procedure/ Other Site | | |  | |
| Regional Nodes Examined | |  | **Systemic Therapy Codes** | | | | |
| Lymphovascular Invasion | |  | Chemotherapy | | |  | |
| PSA Lab value | |  | Hormone Therapy | | |  | |
| Number of Cores Positive | |  | Immunotherapy | | |  | |
| Number of Cores Examined | |  | Hematologic Transplant/Endocrine Procedure | | |  | |
| Gleason Score Clinical | |  | Systemic/Surgery Sequence | | |  | |
| Gleason Patterns Clinical | |  |  | | |  | |
| Gleason Score Pathological | |  |  | | |  | |
| Gleason Patterns Pathological | |  |  | | |  | |
| Gleason Tertiary Pattern | |  |  | | |  | |